A novel approach to safer glucocorticoid receptor–targeted anti-lymphoma therapy via REDD1 (regulated in development and DNA damage 1) inhibition

Lesovaya E.A. ^{1, 2} , Savinkova A.V.¹ , Morozova O.V.¹ , Lylova E.S.¹ , Zhidkova E.M.¹ , Kirsanov K.I. ^{1, 3} , Yakubovskaya M.G. ¹ , Kulikov E.P.² , Klopot A.⁴ , Baida G.⁴ , Budunova I.⁴ , Gordon L.I.⁵ , Readhead B.^{6, 7} , Dudley J.T.^{6, 7}

MOLECULAR CANCER THERAPEUTICS

AMER ASSOC CANCER RESEARCH

9

English

1898-1908

Published

19

2020

• ¹ N.N. Blokhin NMRCO
• ² I.P. Pavlov Ryazan State Medical University
• ³ RUDN University
• ⁴ Department of Dermatology|Northwestern University
• ⁵ Division of Hematology Oncology|Northwestern University
• ⁶ Department of Genetics and Genomic Sciences|Icahn School of Medicine at Mount Sinai
• ⁷ Icahn Institute of Genomics and Multiscale Biology|Icahn School of Medicine at Mount Sinai